Dianthus Therapeutics (DNTH) Stock: Buy, Sell, or Hold?
DNTH - Dianthus Therapeutics, Inc. Common Stock
$106.20
2.92 (2.83%)
▲
5d:
-1.53%
30d:
-5.52%
90d:
+38.91%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When DNTH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DNTH shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DNTH shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: DNTH is currently trading at $106.20, which is considered oversold relative to its 30-day fair value range of $106.72 to $112.93.
Technical Outlook: Technically, DNTH is in a strong uptrend. Immediate support is located at $101.60, while resistance sits at $111.31.
Market Sentiment: DNTH scores 27/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $141.21 (+33.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DNTH is in a strong uptrend. Immediate support is located at $101.60, while resistance sits at $111.31.
Market Sentiment: DNTH scores 27/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $141.21 (+33.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$106.72 -
$112.93
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
Protect Your Profits
Holding DNTH? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (27/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 33.0% below Wall St target ($141.21)
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$106.72 -
$112.93
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$10.50
(9.9%)
Support & Resistance Levels
Support Level
$101.60
Resistance Level
$111.31
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-23.01
Wall Street Target
$141.21
(+33.0%)
Revenue Growth (YoY)
294.3%
Share & Embed Analysis
Last updated: September 12, 2026 4:28 AM ET
Data refreshes hourly during market hours. Next update: 5:28 AM
Data refreshes hourly during market hours. Next update: 5:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DNTH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Ryan Savitz
SELL
8224 shares
2026-04-09
Ryan Savitz
SELL
114367 shares
2026-03-31
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 50 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$289 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$34 | 52 HOLD |
Advanced DNTH Option Strategies
Professional options setups generated by AI based on today's DNTH price and gamma walls.
